We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of a Drug and Placebo in the Prevention of Migraine Headaches

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01122381
Recruitment Status : Terminated (poor recruitment)
First Posted : May 13, 2010
Results First Posted : August 19, 2015
Last Update Posted : August 19, 2015
Sponsor:
Collaborators:
Thomas Jefferson University
University of Pittsburgh
Information provided by (Responsible Party):
VA Office of Research and Development ( US Department of Veterans Affairs )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to determine whether ethosuximide works better than placebo in the prevention of episodic migraine among veterans.

Condition or disease Intervention/treatment Phase
Headache, Migraine Drug: ethosuximide Other: placebo comparator Phase 1 Phase 2

Detailed Description:

Chronic and episodic headaches in veteran populations include migraine, transformed migraine, and post-traumatic headache with migrainous features. More and better prophylactic drugs with fewer side effects (such as weight gain) are needed to treat these disabling, refractory conditions which generally have less than a 50% response rate to preventative treatments.

Rare forms of severe familial hemiplegic migraine (FHM) are considered channelopathies and can be caused by mutations in a calcium channel gene. Serotonin is also known to be a critical neurotransmitter in migraine based on the pharmacology of acute and preventative treatments. We previously identified a "migraine" signaling pathway in an invertebrate C. elegans "hemiplegic migraine" model of a mutant calcium channel upstream from transforming growth factor-beta (TGF-beta) and showed that low serotonin levels can be rescued by treatment with the childhood antiepileptic drug ethosuximide (ESX).

Objective: We propose to test our findings from this invertebrate migraine model to determine its relevance to humans in the prevention of episodic migraine.

Primary Aim: Determine whether ethosuximide (ESX) will be significantly more effective than placebo in reducing migraine headache days. We propose a 3 year, double blind, phase 1/2 randomized, 2:1 ESX:placebo controlled parallel trial in episodic migraineurs comparing migraine headache days during the last 4 weeks of treatment to a pre-treatment 4 week baseline.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Pharmacologic and Genetic Evaluation of a C. Elegans Model for Migraine
Study Start Date : December 2011
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Migraine
MedlinePlus related topics: Headache Migraine

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm 1-ethosuximide
ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed "30mg"/kg/d) vs maximum tolerability
 Drug: ethosuximide
ethosuximide (ESX)
Other Name: zarontin
Placebo Comparator: Arm 2-placebo comparator
placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed "30mg"/kg/d) vs maximum tolerability
 Other: placebo comparator
placebo


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Migraine Headache Days Per 4 Week Period Comparing the Last 4 Weeks of Treatment to a 4 Week Pre-treatment Baseline. [ Time Frame: 4 weeks, end of treatment and pre-treatment baseline ]

    Compare number of migraine headache days pre and post treatment between the ESX and placebo group.

    Study terminated early-no outcome data available. The single subject assigned to study drug did not actually take it according to subsequent review of ESX drug levels.



Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must be a veteran.
  • The number of migraine days per 4-week period is to be 4-14 for a period of 3 months prior to screening for entry into the trial.
  • Migraine must have been occurring for 6 months preceding entry into the trial and age of onset should be before age 60 years.
  • Migraine must be at least moderate severity and interrupt daily activities in some respect at least 3 times per month.
  • As long as the veteran can easily distinguish nonmigraine headaches from migraine, there is no limit on the number of non migraine headache days allowed. "Transformed migraine" headaches due to medication over usage will be excluded according to exclusion criteria #4.
  • Migraine diagnosis:

Veterans with headache must have migraine categorized using the International Headache Society (I.H.S.) criteria as illustrated below for the two main types with and without aura.

Criteria for migraine without aura (I.H.S. 1.1)

  • > 5 attacks
  • headache lasting 4-72 hours when untreated or not successfully treated.

  • headache with two of the following characteristics

    • unilateral,
    • pulsating,
    • moderate to severe intensity,
    • aggravation by exertion.

  • one of the following occurs with headache

    • nausea and/or vomiting
    • photophobia and phonophobia

Criteria for migraine with aura (I.H.S. 1.2)

  • at least 2 attacks

  • at least three of the following characteristics:

    • One or more fully reversible aura symptoms indicating focal cerebral cortical - and/or brain stem dysfunction.

One or more aura symptoms of the following types:

  • Homonymous visual disturbance
  • Unilateral parenthesis and/or numbness
  • Unilateral weakness

  • Aphasia or unclassifiable speech difficulty

    • At least one aura symptom develops gradually over more than 4 minutes or, 2 or more symptoms occur in succession.
    • No aura symptom lasts more than 60 minutes. If more than one aura symptom is present, accepted duration is proportionally increased.
    • Headache follows aura with a free interval of less than 60 minutes. (It may also begin before or simultaneously with the aura). Headache, nausea and/or photophobia usually follow neurological aura symptoms directly or after a free interval of less than an hour. The headache usually lasts 4-72 hours, but may be completely absent (1.2.5, acephalgic migraine).

Exclusion Criteria:

  • Veterans with migraine plus other systemic disorder will be excluded if migraine onset was temporally related to onset of the systemic disorder.
  • Blood pressure elevations (must be < borderline values 135/85 for 4 weeks before enrollment into the study). Current treatment for hypertension with beta-blockers, calcium channel blockers, or ace inhibitors not allowed.
  • Use of other prophylactic migraine drugs (requires a washout phase) and cannot have failed more than two other prophylactic drugs for migraine.
  • Excessive use of acute pain medicines, including narcotics (>10 days month). Those using non-narcotics could be tapered off over 4-8 weeks.
  • Receiving disability or seeking disability for headache or chronic pain.
  • Significant neck pain or cervicogenic contributors to chronic headache.
  • Significant depression, anxiety, post-traumatic stress disorder, or other disabling psychiatric condition.
  • Known allergies or serious side effects with ESX or succinimides in the past.
  • Known liver or significant renal disease.
  • Women veterans of child-bearing age who do not have adequate birth control.
  • Chronic bone marrow suppression.
  • Using psychogenic or other sedating maintenance drugs.
  • History of porphyria.
  • History of cluster headache. 15.History of other CNS disease.
  • Age younger than 18 years and greater than 65.
  • Women veterans who are breastfeeding.
  • Veterans with familial hemiplegic migraine (FHM).

Ongoing exclusions during the study:

  • The addition of other migraine prophylactic headache medicines is not allowed. 2. New drugs cannot be added that aggravate headache (nitrates, dipyridamole, niacin).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01122381


Locations
Layout table for location information
United States, Pennsylvania
VA Pittsburgh Health Care System
Pittsburgh, Pennsylvania, United States, 15240
Sponsors and Collaborators
US Department of Veterans Affairs
Thomas Jefferson University
University of Pittsburgh
Investigators
Layout table for investigator information
Principal Investigator: Kathy L Gardner, MD VA Pittsburgh Health Care System
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: US Department of Veterans Affairs
ClinicalTrials.gov Identifier: NCT01122381    
Other Study ID Numbers: B5043-R
First Posted: May 13, 2010    Key Record Dates
Results First Posted: August 19, 2015
Last Update Posted: August 19, 2015
Last Verified: August 2015
Keywords provided by VA Office of Research and Development ( US Department of Veterans Affairs ):
headache, migraine
depression
disability evaluation
weight gain
Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
 Nervous System Diseases
Pain
Neurologic Manifestations
Ethosuximide
Anticonvulsants